Neoleukin Therapeutics IncNASDAQ:NLTXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5901
- TODAY'S CHANGE (%)0.0118 (2.0405%)
- Bid / Lots0.5900/ 2
- Ask / Lots0.6000/ 1
- Open / Previous Close0.6090 / 0.5783
- Day Range
- 52 Week Range
- Volume160,071
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NLTX |
|---|---|---|
| 09:32 ET | 161 | 0.609 |
| 09:39 ET | 179 | 0.61 |
| 09:42 ET | 100 | 0.61 |
| 09:44 ET | 1108 | 0.600001 |
| 09:51 ET | 1284 | 0.599999 |
| 10:08 ET | 225 | 0.5801 |
| 10:27 ET | 100 | 0.5803 |
| 10:31 ET | 3000 | 0.580201 |
| 10:38 ET | 11600 | 0.5802 |
| 10:54 ET | 200 | 0.6001 |
| 10:56 ET | 200 | 0.5868 |
| 11:00 ET | 100 | 0.619899 |
| 11:03 ET | 750 | 0.6185 |
| 11:12 ET | 170 | 0.599349 |
| 11:27 ET | 1000 | 0.5991 |
| 11:30 ET | 3300 | 0.5802 |
| 11:48 ET | 24196 | 0.5806 |
| 11:50 ET | 35312 | 0.581 |
| 11:54 ET | 900 | 0.5995 |
| 11:56 ET | 100 | 0.5995 |
| 11:57 ET | 900 | 0.5995 |
| 11:59 ET | 400 | 0.604 |
| 12:01 ET | 10600 | 0.604 |
| 12:03 ET | 700 | 0.6 |
| 12:06 ET | 200 | 0.604 |
| 12:08 ET | 3019 | 0.6 |
| 12:10 ET | 200 | 0.6 |
| 12:15 ET | 5455 | 0.618 |
| 12:17 ET | 7600 | 0.6176 |
| 12:19 ET | 100 | 0.604 |
| 12:21 ET | 7600 | 0.5997 |
| 12:26 ET | 200 | 0.608 |
| 12:28 ET | 100 | 0.6047 |
| 12:33 ET | 1000 | 0.6042 |
| 12:35 ET | 1069 | 0.6177 |
| 12:44 ET | 1500 | 0.617899 |
| 12:53 ET | 300 | 0.6078 |
| 01:02 ET | 500 | 0.6044 |
| 01:06 ET | 100 | 0.6078 |
| 01:09 ET | 100 | 0.6078 |
| 01:24 ET | 700 | 0.6078 |
| 01:26 ET | 100 | 0.61 |
| 01:27 ET | 348 | 0.6006 |
| 02:20 ET | 1000 | 0.6068 |
| 02:30 ET | 300 | 0.5999 |
| 03:33 ET | 11440 | 0.6299 |
| 03:35 ET | 2600 | 0.6318 |
| 03:37 ET | 8391 | 0.6243 |
| 03:46 ET | 350 | 0.615 |
| 03:48 ET | 100 | 0.6196 |
| 03:57 ET | 4331 | 0.5901 |
| 04:00 ET | 500 | 0.5901 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neoleukin Therapeutics Inc | 25.1M | -0.5x | --- |
Rubius Therapeutics Inc | 25.2M | -0.1x | --- |
Elevation Oncology Inc | 24.7M | -0.3x | --- |
Chemomab Therapeutics Ltd | 25.6M | -0.1x | --- |
Check Cap Ltd | 24.7M | -4.4x | --- |
Applied Molecular Transport Inc. | 24.1M | -0.2x | --- |
Company Information
Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.
Contact Information
- Headquarters
- 1616 Eastlake Ave E Ste 360SEATTLE, WA, United States 98102-3795
- Phone
- 206-732-2133
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Todd Simpson
- President, Chief Executive Officer, Principal Financial Officer, Director
- Jonathan Drachman
- Senior Vice President Legal, General Counsel
- Donna Cochener
- Senior Vice President - Corporate Development
- Carl Walkey
- Vice President, Head of Research
- Bill Arthur
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 42.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.17 |
EPS | $-1.07 |
Book Value | $3.36 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
